FMP
Nov 28, 2022(Last modified: Dec 19, 2023)
Medtronic (NYSE:MDT) reported its Q2 results on Tuesday, with EPS of $1.30 coming in better than the Street estimate of $1.28. Revenue was $7.6 billion, compared to the Street estimate of $7.7 billion.
Management noted supply chain issues (particularly in Surgical Innovations) took longer than expected to resolve in Q2, impacting the H2 ramp (including lost sales to a competitor, sales management anticipates recapturing).
The company expects fiscal 2023 EPS to be in the range of $5.25-$5.30, compared to the Street estimate of $5.53. Management anticipates H2/2023 revenue growth in the range of 3.5%-4.0% on an organic basis, an acceleration over H1.

In times of rising geopolitical tension or outright conflict, defense stocks often outperform the broader market as gove...

As Circle Internet (NYSE:CRCL) gains attention following its recent public listing, investors are increasingly scrutiniz...

LVMH Moët Hennessy Louis Vuitton (OTC:LVMUY) is a global leader in luxury goods, offering high-quality products across f...